tbuckley/cabot-search huggingface dataset:
Clinical utility of profiling somatic alterations in Indian cancer patients using a multi-gene next generation sequencing (NGS) test.
Authors: Urvashi Bahadur, Aarthi Ravichandran, Shataparna Banerjee, Shreya Paliwal, Roopa Rayanur Sripathi, Ruthika Javaray, Anusha NJ, Gulrez Chahal, Nanda Pandey, Hima Varghese, Satish Sankaran, Disha Awasthy, Manasa B.P., Smita Agarwal, Mithua Ghosh, Sheela ML, Ramesh Hariharan, Preveen Ramamoorthy, Vamsi Veeramachaneni, Kalyanasundaram Subramanian
Journal: Journal of Clinical Oncology (2015)

e22127 Background: NGS allows for comprehensive profiling of a tumor genotype across multiple genes. Such molecular profiling can identify key driver mutations with potential to impact therapeutic decisions. We sought to evaluate the utility of an NGS multi-gene panel based approach in delivering therapeutically relevant insights that could affect treatment choices. Methods: DNA from formalin-fixed, paraffin-embedded blocks of 260 patients was sequenced on a MiSeq using a 48 gene hotspot panel from Illumina. Data was processed and analyzed using Strand NGS and mutations detected assessed for potential impact on response to therapy (actionability) and clinical relevance. Results: Clinical samples obtained encompassed 47 tumor types. The most common tumor types studied were breast (32%), colon (10%), lung (9%), sarcomas (7%) and ovarian (5%). The primary genes altered were TP53 (50%), PTEN (16%), PIK3CA (14%) and KRAS(13%). Most alterations detected affected the MAPK (24.5% across 20 cancers) or PI3K pathway (20.4% across 19 cancers). Among the more common tissue types (N > 10), the highest percentage of actionable alterations (AAs) was observed in colorectal cancer (82%) and lowest in sarcomas (53%). AAs that would not have been detected by conventional testing were observed in 24% (5/21) of lung and 20% (5/25) of colorectal cancers. In 45% of the cases, alterations detected could potentially impact response to therapy approved for that tumor type, while in 35% of the cases, AAs indicated probable response to alternative targeted therapy, either approved or in trials. Furthermore, more than one cancer pathway could be targeted in 15.6% of the cases, underscoring the relevance of NGS-based multi-gene testing to obtain accurate insights. In all, at least one AA was identified in 68% of the cases with the average number of AAs being 1.6, thus illustrating the suitability of this panel for a variety of tissue types. Conclusions: These data thus demonstrate the utility of multi-gene testing in a clinical setting by: (a) identifying additional clinically actionable variants compared to single gene testing (b) providing genotypically matched novel therapeutic options.
Periostin: An emerging biomarker for allergic diseases
Authors: Kenji Izuhara, Satoshi Nunomura, Yasuhiro Nanri, Junya Ono, Masayuki Takai, Atsushi Kawaguchi
Journal: Allergy (2019)

Periostin is a matricellular protein as well as an extracellular matrix (ECM) protein belonging to the fasciclin family. Periostin plays important roles as a matricellular protein in the setting of allergic diseases by binding to several integrins on various cells. Since periostin is induced mainly by IL-4 and IL-13, signature type 2 cytokines, and it is highly expressed in the subepithelial regions of many chronic allergic diseases, periostin has emerged as a novel biomarker reflecting type 2 inflammation in allergic diseases. It has, moreover, been revealed that periostin has characteristics different from other type 2 biomarkers such as eosinophil count and fractional exhaled nitric oxide (FeNO), reflecting fibrosis or tissue remodeling. From this, we may say that serum periostin is a "chronic" type 2 biomarker, whereas FeNO and possibly the eosinophil count are "acute" type 2 biomarkers. In contrast, it is still uncertain how we can apply periostin measurement to the use of biologics for allergic diseases. By examining the roles of periostin in allergy and the utility and potential of periostin in developing diagnostics against allergic diseases, it is hoped that in the near future, we can develop a new strategy to treat allergic patients.
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study
Authors: Marco Carbone, yllka kodra, adele rocchetti, valerio manno, giada minelli, Alessio Gerussi, Vincenzo Ronca, Federica Malinverno, Laura Cristoferi, Annarosa Floreani, Pietro Invernizzi, susanna conti, domenica taruscio
Journal: Journal of Hepatology (2019)
FRI-149-Comprehensive transcriptome analysis of liver biopsies from chronically infected HBV patients
Authors: Ricardo Ramirez, Nick van Buuren, Vithika Suri, Neeru Bhardwaj, Nam Bui, Li Li, Patrick Marcellin, Henry Chan, Maria Buti, Anuj Gaggar, Becket Feierbach
Journal: Journal of Hepatology (2019)
PS-157-Gut microbiome signature for cirrhosis due to non-alcoholoic fatty liver disease: A prospective twin and family study
Authors: Cyrielle Caussy, Anupriya Tripathi, Greg Humphrey, Shirin Bassirian, Seema Singh, Claire Faulkner, Ricki Bettencourt, Emily Rizo, Lisa Richards, Zhenjiang Xu, Micheal Downes, Ronald E. Evans, David A. Brenner, Claude B. Sirlin, Rob Knight, Rohit Loomba
Journal: Journal of Hepatology (2019)
Towards precision medicine: Cataloging FDA-approved actionable mutations in The Cancer Genome Atlas.
Authors: Tu Dan, Joshua David Palmer, Mark Vikas Mishra
Journal: Journal of Clinical Oncology (2015)

e22198 Background: A major goal of The Cancer Genome Atlas (TCGA) is to identify actionable mutations using next generation genomic data. There are currently 7 actionable mutations across 6 cancer types identified in the TCGA with an FDA-approved intervention and associated companion diagnostic. The primary aim of this study was to identify the incidence of currently available actionable mutations. A secondary aim of the study was to analyze the cost of associated companion diagnostics. Methods: Using data from unrestricted datasets generated by the TCGA Research Network, we queried actionable mutations by analyzing somatic mutations, DNA copy-number alterations, and mRNA expression across 6 different cancer types (Ovarian, Colon, Lung, Breast, Gastric, and Melanoma). Actionable mutations were strictly defined as mutations with a FDA-approved drug with a disease-specific indication and associated companion diagnostic. Based on manufacturer list price, we calculated the cost of applying each companion diagnostic. Using the SEER database, we estimated the number of patients eligible to use a companion diagnostic. The number needed to screen (NNS) to detect an actionable mutation and costs per patient were then calculated. Results: Overall, we found 27.4% of 1631 samples had an FDA-approved actionable mutation. Based SEER incidence data, approximately 510,000 new patients annually would be eligible for screening of an actionable mutation. Amongst disease sites, metastatic melanoma had the lowest NNS, with only 1.7 patients needing to be screened to detect an actionable mutation. ALK mutations had the highest NNS, requiring screening of 12.5 patients to detect one mutation. The cost per patient using FDA-approved companion diagnostic was calculated to be on average $954.72 per patient. Conclusions: Over one-fourth of patients in the TCGA database were found to have an actionable mutation across 6 disease sites. Currently available companion diagnostics to identify these patients may be price-prohibitive. As the costs of next generation sequencing decreases, high throughput sequencing may be more cost-effective to identify patients that may benefit from targeted therapies.
THU-176-Weight gain after interferon-free clearance of chronic hepatitis C: Results from the German hepatitis C registry (DHC-R)
Authors: Bernhard Schlevogt, Klaus Boeker, Stefan Mauss, Hartwig Klinker, Renate Heyne, Ralph Link, Karl-Georg Simon, Christoph Sarrazin, Michael P. Manns, Heiner Wedemeyer, Deutsches Hepatitis C-Register
Journal: Journal of Hepatology (2019)
SAT-388-How to infuse heterologous human adult liver-derived progenitor cells safely?
Authors: Louise Coppin, Mustapha Najimi, Julie Bodart, Marie-Sophie Rouchon, Patrick Vandersmissen, Eeckhoudt Stephane, Géraldine Dahlqvist, Castanares Diego, Johan Heemskerk, Sandrine Horman, nathalie Belmonte, Etienne Sokal, Xavier Stéphenne
Journal: Journal of Hepatology (2019)
THU-130-Management strategies for drug drug interactions between direct oral anticoagulants and hepatitis C directly acting agents: A multicentre review
Authors: Alison Boyle, Katherine Davidson, Caroline Cassidy, Aniqa Afzal, Anthony Pratt, Sally Midgley, Jacqueline Swabe, Paul Selby, Sital Shah, Aisling Considine, Louise Mcgivern, Joan Mackintosh, Elaine Sheridan, Fiona Marra
Journal: Journal of Hepatology (2019)
HIV Remission After Hematopoietic Stem Cell Transplant
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PS-121-Obeticholic acid limits cholestasis induced cognitive decline by maintaining blood-brain barrier integrity and preserving neuronal health
Authors: Lucy Gee, Ben Millar, Jack Leslie, Claire Richardson, Diana Jurk, Saimir Luli, Marco Youssef William Zaki, Fiona LeBeau, Elizabeth Stoll, David Jones, Fiona Oakley
Journal: Journal of Hepatology (2019)
Donor Leukocyte Infusion for Single Unit Umbilical Cord Blood Transplantation: 5% of Thawed Single Cord Blood Unit Refrozen on Day of Transplant Is Safe with Signals of Efficacy in Improving Donor Derived Immunity
Authors: Mark Vander Lugt, Beth Carella, Heather Stanczak, Xiaohua Chen, Paul Szabolcs
Journal: Blood (2018)
TCTAP A-031 Predictors of Early Adverse Outcomes in Patients Presenting with ST-elevation Myocardial Infarction: Insights from a Tunisian 18-year Registry
Authors: Walid Jomaa, Ouday Ben Abdeljelil, Nesrine Amdouni, Ikram Chamtouri, Khaldoun Ben Hamda, Faouzi Maatouk
Journal: Journal of the American College of Cardiology (2019)
Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence
Authors: Suzanne Sniekers, Sven Stringer, Kyoko Watanabe, Philip R Jansen, Jonathan R I Coleman, Eva Krapohl, Erdogan Taskesen, Anke R Hammerschlag, Aysu Okbay, Delilah Zabaneh, Najaf Amin, Gerome Breen, David Cesarini, Christopher F Chabris, William G Iacono, M Arfan Ikram, Magnus Johannesson, Philipp Koellinger, James J Lee, Patrik K E Magnusson, Matt McGue, Mike B Miller, William E R Ollier, Antony Payton, Neil Pendleton, Robert Plomin, Cornelius A Rietveld, Henning Tiemeier, Cornelia M van Duijn, Danielle Posthuma
Journal: Nature Genetics (2017)
THU-394-Cancer risk among people with HIV, HBV, and/or HCV infections
Authors: Maryam Darvishian, Carmine Rossi, Stanley Wong, Amanda Yu, Ryan Woods, Mawuena Binka, Zahid A Butt, Jane Buxton, Sofia Bartlett, Dr. Margo Pearce, Dr. Jason Wong, Dr. Mark Gilbert, Troy Grennan, Maria Alvarez, Darrel Cook, Eric Yoshida, John Spinelli, Mark Tyndall, Mel Krajden, Naveed Janjua
Journal: Journal of Hepatology (2019)
LBP-30-Changes in Serum Bile Acids Correlate with 7alpha-Hydroxy-4-Cholesten-One and Fibrogenesis Biomarker Pro-C3 with NGM282 Therapy in Patients with Non-alcoholic Steatohepatitis
Authors: Arun Sanyal, Lei Ling, Mark Jaros, Bryan Baxter, Kris V. Kowdley, Alex DePaoli, Stephen Harrison
Journal: Journal of Hepatology (2019)
Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity
Authors: Chaya D. Patel, Iara M. Backes, Sean A. Taylor, Yike Jiang, Arnaud Marchant, Jean M. Pesola, Donald M. Coen, David M. Knipe, Margaret E. Ackerman, David A. Leib
Journal: Science Translational Medicine (2019)

Maternal immunization confers antibody-mediated protection against neonatal HSV, preventing mortality and long-term behavioral sequelae in a mouse model.
PS-155-HBV entry inhibition after interferon alpha treatment hinders HBV rebound in hepatocytes that became negative for all HBV markers during interferon treatment
Authors: Lena Allweiss, Katja Giersch, Tassilo Volz, Ansgar W. Lohse, Jörg Petersen, Stephan Urban, Marc Luetgehmann, Maura Dandri
Journal: Journal of Hepatology (2019)
LBP-36-Inhibition of glutamine synthetase in monocytes from patients with Acute-on-Chronic Liver Failure resuscitates their antibacterial and inflammatory capacity
Authors: Hannelie Korf, Johannie Du Plessis, Jos van Pelt, Sofie De Groote, David Cassiman, Len Verbeke, Bart Ghesquière, Sarah-Maria Fendt, Matthew Bird, Ali Talebi, Matthias Van Haele, Rita Feio-Azevedo, Lore Meelberghs, Tania Roskams, Rajeshwar Mookerjee, Gautam Mehta, Rajiv Jalan, Thierry Gustot, Wim Laleman, Frederik Nevens, Schalk van der Merwe
Journal: Journal of Hepatology (2019)
SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity
Authors: Noelia Keiran, Victoria Ceperuelo-Mallafré, Enrique Calvo, Maria Isabel Hernández-Alvarez, Miriam Ejarque, Catalina Núñez-Roa, Daniel Horrillo, Elsa Maymó-Masip, M. Mar Rodríguez, Rosa Fradera, Juan Vladimir de la Rosa, Rosa Jorba, Ana Megia, Antonio Zorzano, Gema Medina-Gómez, Carolina Serena, Antonio Castrillo, Joan Vendrell, Sonia Fernández-Veledo
Journal: Nature Immunology (2019)
Genotyping and monitoring of circulating tumor DNA in lung cancer patients during the early period of EGFR-TKI treatment using deep sequencing.
Authors: Junji Uchida, Kikuya Kato, Yoji Kukita, Toru Kumagai, Kazumi Nishino, Haruko Daga, Izumi Nagatomo, Shigeyuki Oba, Yuri Ito, Koji Takeda, Fumio Imamura, Takako Inoue, Madoka Kimura
Journal: Journal of Clinical Oncology (2015)

e19083 Background: Circulating tumor DNA (ctDNA) is a promising biomarker in oncology. ctDNA carries genetic information from malignant tumors and can be obtained from peripheral blood samples. The genotyping of EGFR mutations will be beneficial for therapeutic decision making for lung cancers treated with EGFR-TKI. The dynamics of ctDNA may provide key information for evaluating the response to EGFR-TKI. Methods: We developed a detection system for EGFR mutations in ctDNA using a massively parallel DNA sequencer. We conducted a multi-institute prospective study to evaluate the system, enrolling 288 patients. We performed a prospective exploratory analysis of 21 patients in parallel to measure ctDNA levels during the early period (0-20 days) of EGFR-TKI treatment. Results: The performance of the detection system was evaluated along with the genotyping results from biopsy samples as a comparator: sensitivity for exon 19 deletions, 50.9% (95% confidence interval, 37.9–63.9); specificity for exon 19 deletions, 98.0% (88.5-100); sensitivity for L858R, 51.9% (38.7–64.9); and specificity for L858R, 94.1% (83.5-98.6). The overall sensitivities were as follows: all cases, 54.4% (44.8–63.7); stage IA–IIIA, 22.2% (11.5-38.3); stage IIIB–IV, 72.7% (60.9–82.1). The exploratory analysis revealed a decrease in ctDNA levels in response to EGFR-TKI as well as transient increases that were likely a consequence of cancer cell destruction by EGFR-TKI. The transient increases in some patients had heterogeneous mutation types and/or timing, indicating the presence of heterogeneous lesions. Conclusions: Deep sequencing of cell-free plasma DNA can be used for genotyping as well as for monitoring the dynamics of ctDNA. Because ctDNA is released from dying cancer cells, ctDNA dynamics provide information, such as increasing death of new cancer cells from cytotoxic reagents/molecular target drugs. Clinical trial information: UMIN000006762.
BRCA1—No Matter How You Splice It
Authors: Dan Li, Lisa M. Harlan-Williams, Easwari Kumaraswamy, Roy A. Jensen
Journal: Cancer Research (2019)

Abstract BRCA1 (breast cancer 1, early onset), a well-known breast cancer susceptibility gene, is a highly alternatively spliced gene. BRCA1 alternative splicing may serve as an alternative regulatory mechanism for the inactivation of the BRCA1 gene in both hereditary and sporadic breast cancers, and other BRCA1-associated cancers. The alternative transcripts of BRCA1 can mimic known functions, possess unique functions compared with the full-length BRCA1 transcript, and in some cases, appear to function in opposition to full-length BRCA1. In this review, we will summarize the functional “naturally occurring” alternative splicing transcripts of BRCA1 and then discuss the latest next-generation sequencing–based detection methods and techniques to detect alternative BRCA1 splicing patterns and their potential use in cancer diagnosis, prognosis, and therapy.
FRI-229-Reflex testing in patients with chronic hepatitis C in Spain improves healthcare outcomes and is cost effective
Authors: Federico Garcia Garcia, Raquel Dominguez, Juan Carlos Alados Arboledas, Marta Casado, Juan Macias Sanchez, Francisco Téllez Pérez, Juan Manuel Pascasio, Miguel Ángel Casado
Journal: Journal of Hepatology (2019)
THU-151-Real-world effectiveness and safety of glecaprevir plus pibrentasvir in HCV: A multi-country analysis of postmarketing observational studies
Authors: Pietro Lampertico, Markus Peck, Mark Bondin, Yves Horsmans, Nasser Semmo, Sadhana Sonparote, Zhenzhen Zhang, Ariel Porcalla, Dominique Thabut
Journal: Journal of Hepatology (2019)
Upper Airway Video Endoscopy: Assessment of the response to positive pressure ventilation and mechanical in-exsufflation
Authors: B. Conde, N. Martins, M. Brandão, A.C. Pimenta, J.C. Winck
Journal: Pulmonology (2019)

Upper airways (UA) include the nasal cavities, pharynx, and larynx, and its main function is to warm and filter the inspired air. UA dysfunction is in the pathogenesis of various disorders, such as obstructive sleep apnea syndrome (OSAS) and vocal cord dysfunction. In addition, in some neurodegenerative diseases (e.g. Amyotrophic Lateral Sclerosis – ALS), UA dysfunction may also compromise the effective use of ventilatory support (VS). In this context, the endoscopic evaluation of UA may be useful in understanding the OSAS mechanisms, in determining the causes for treatment-induced airway obstruction and even in helping to titrate noninvasive ventilation (NIV) in ALS patients with bulbar or pseudo-bulbar (spastic) dysfunction. Specifically, in OSAS patients, when residual obstructive events persist, although an optimal ventilatory mode has been apparently achieved, along with interface and equipment, the endoscopic evaluation of UA seems to be a valuable tool in understanding its mechanisms, even assisting adjustments to NIV parameters. In addition, it has also been described as being useful in laryngeal response to mechanical in-exsufflation (MI-E) and Exercise-Induced Laryngeal Obstruction (EILO). However, no protocol has yet been published or validated for this. For this reason, a literature review was conducted on UA function and its response to positive pressure and MI-E. Special emphasis has also been given to the current indication for video endoscopy in chronically ventilated patients.
FRI-201-Hepatitis B virus vaccine immunogenicity in anti-HBC+ immunocompromised patients with low anti-HBS levels: Preliminary results of the Hepbare study
Authors: Judit Vidal-González, Mar Riveiro-Barciela, Xavier Martínez, Basilio Rodríguez, Virginia Robles, Gloria Aparicio, Lluís Castells, Manel Perelló, Cristina Berastegui, Itxarone Bilbao, Rafael Esteban, Magda Campins, Maria Buti
Journal: Journal of Hepatology (2019)
SAT-058-In hepatic cirrhosis, the systemic levels of short chain fatty acids inversely correlate with the level of endotoxemia, and are negatively associated with an increased inflammatory response, impaired liver function and a higher HVPG
Authors: Oriol Juanola, José A Ferrusquia, Pedro Zapater, Rocío García-Villalba, Marta Magaz, Alicia Marín, Pablo Bellot, Anna Baiges, Fanny Turon, Virginia Hernández-Gea, José M González-Navajas, Francisco A. Tomás, Juan C García-Pagán, Rubén Francés
Journal: Journal of Hepatology (2019)
FRI-173-Modeling HBV kinetics in mice treated by a novel TLR7 agonist, alone or in combination with entecavir
Authors: Goncalves Antonio, Lemenuel-Diot Annabelle, Gao Lu, Dai Lue, Alvarez Ruben, Grippo Joseph, Jeremie Guedj
Journal: Journal of Hepatology (2019)
THU-501-Myeloid-specific IRE1 alpha deletion reduces tumour development in a non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model
Authors: Sanne Van Campenhout, Sander Lefere, Astrid Vandierendonck, Xavier Verhelst, Anja Geerts, Hans Van Vlierberghe, Lindsey Devisscher
Journal: Journal of Hepatology (2019)
Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells
Authors: Stefanie Sperling, Petra Fiedler, Markus Lechner, Anna Pollithy, Stefanie Ehrenberg, Ana-Iris Schiefer, Lukas Kenner, Annette Feuchtinger, Ralf Kühn, Gene Swinerd, Marc Schmidt-Supprian, Lothar J. Strobl, Ursula Zimber-Strobl
Journal: Blood (2019)
Protecting those who serve: are we doing enough to prevent tuberculosis in healthcare workers?
Authors: Jennifer Furin, Giovanni Sotgiu
Journal: European Respiratory Journal (2019)

The continuous flow of scientific articles on high tuberculosis (TB) morbidity and mortality over the past decades highlight a partial or total failure of national and local policies to address a potentially curable and preventable infectious disease. The ongoing transmission of Mycobacterium tuberculosis strains in the community and in healthcare settings proves the inability of the system to epidemiologically reverse the natural history of this ancient disease. Ironically, these hospitals and health centres, places where people go for healing, are places of high risk for TB infection and disease for those attending inpatient and outpatient settings, including for healthcare workers. Tuberculosis in healthcare workers can be prevented <http://ow.ly/Xke330o6B0N>
Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer
Authors: Jie Dai, Ming Liu, Yang Yang, Qiuyuan Li, Nan Song, Gaetano Rocco, Alan D.L. Sihoe, Diego Gonzalez-Rivas, Hon Chi Suen, Wenxin He, Liang Duan, Jiang Fan, Deping Zhao, Haifeng Wang, Yuming Zhu, Chang Chen, Robert B. Diasio, Gening Jiang, Ping Yang, Peng Zhang
Journal: Journal of Thoracic Oncology (2019)
The basophil‐<scp>IL</scp>‐4‐mast cell axis is required for food allergy
Authors: Jun‐Ichi Kashiwakura, Tomoaki Ando, Hajime Karasuyama, Masato Kubo, Kenji Matsumoto, Tadashi Matsuda, Toshiaki Kawakami
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
LBP-13-Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort
Authors: Stuart C Gordon, Yueren Zhou, Jia Li, Loralee B Rupp, Joseph A. Boscarino, Yihe G Daida, Mark A Schmidt, Sheri Trudeau, Mei Lu
Journal: Journal of Hepatology (2019)